Lumea

Tissue devices, a cleared viewer and a laboratory system, with one learned tool of its own. Most of what Lumea sells works without a model: biopsy chips, boards and frames that keep specimens oriented, RFID chain of custody tracking, the Viewer+ image viewer, whose FDA clearance rests on image rendering and measurement tests, and BxLink, a laboratory information system. The company's own learned component is BxCamera, a grossing camera it describes as machine learning trained on more than 2 million specimens that measures and documents specimens. The diagnostic algorithms in its marketplace, from Paige, Deep Bio, Artera, Primaa and others, are the partners' own, not the company's.

Artificial intelligence is a feature layer on products whose value stands without it.

Automated measurement is claimed, with no check on the values it enters. BxCamera measures and documents specimens in seconds and auto-populates the laboratory information system, and the company says it "ensures every specimen is handled with the same high level of quality and precision." Nothing describes who confirms the measurements before they enter the gross description, or what happens when a fragment is missed or mismeasured. Diagnosis stays with the pathologist, and the Viewer+ clearance makes the reading pathologist responsible for image quality and for returning to glass where needed. Partner algorithms in the workspace carry their own oversight, and nothing says what Lumea requires of them.

Automation claimed with oversight not described as a control.

The suppliers of the diagnostic models are named; Lumea's own model is described only by scale. The marketplace names each partner algorithm and, for most, its maker, including Paige's prostate and urine cytology tools, Deep Bio's DeepDx Prostate, AiryDx, Artera's prostate test, PANProfiler Colorectal and Primaa's Cleo Skin. BxCamera is described as machine learning trained on more than 2 million specimens with sub-millimeter precision for length, width and area, with no model type, version or update practice published, and nothing says how partner model versions are tracked on the platform.

Suppliers named without the version and update discipline.

The host and the model providers are named, with the data terms between them unstated. Lumea's privacy notice says data are stored on Amazon Web Services, BxCamera is Lumea's own model, and the marketplace names the partners whose algorithms run on patient images, including Paige, Deep Bio, Artera and Primaa, alongside molecular test companies whose orders pass through BxLink. Nothing says whether partner algorithms run inside Lumea's environment or receive images on their own infrastructure, what they retain, or which other subprocessors handle patient data.

Substantial partial disclosure, with the host and model providers named.

Published research on the tissue devices, and none on the viewer's clinical use or the company's model. The Viewer+ 510(k) summary (K242244) rests on bench testing, a pixel-wise comparison with the predicate viewer, turnaround time and measurement accuracy, not a clinical reader study. Peer reviewed evidence concerns the biopsy chip: a study in the American Journal of Clinical Pathology (2019) on prostate biopsy processing cost, test time and diagnostic material, and a 2016 urology abstract reporting higher cancer detection and tissue available, alongside company white papers on core length, fragmentation and specimen cancellations. BxCamera is described as used on over 2 million specimens with no evaluation published.

Published research short of independent validation, for the tissue devices.

A privacy notice reaches the platform, without answering what reaches a model. Lumea's notice of privacy practices covers the protected health information its customers and their patients entrust to it: data stored on Amazon Web Services, access limited by unit and login, staff trained annually, and patient information never used in marketing or sold. It also permits use and disclosure of de-identified data and limited data sets, and research access. Nothing says whether customer images or specimen photos train BxCamera or other models, what partner algorithms retain, or how long images are kept. Whole slide files carry a slide label photo by default. No safety engineering is published.

General assurances that do not answer what reaches a model.

Business associate status is stated in a privacy notice that reaches the platform. Lumea's notice of privacy practices, linked from every page footer, says that where its customers are covered entities Lumea is a business associate with direct regulatory and contractual responsibilities under HIPAA and business associate agreements, stores data on Amazon Web Services, restricts access by unit, and requires business associates it uses to protect PHI. The site adds that the platform is maintained in compliance with HIPAA and HITECH and that compliance documentation is available before purchase. The agreement itself is not published, and the notice dates from 2022.

Status stated and supported by a substantive privacy document, with the agreement unpublished.

Controls are asserted, with nothing independent behind them. The site's answer on security says connections are encrypted and authenticated, compliance documentation is available on request and an information security officer can answer questions, and it reminds customers that endpoint security is theirs. The privacy notice describes unique logins, access by unit, annual staff training and storage on Amazon Web Services, whose certifications are the host's. Beyond the privacy notice, the site publishes no SOC 2 report, HITRUST or ISO 27001 certification, trust center or penetration testing statement.

The viewer is cleared; the AI is not, and the platform carries the cleared label. Viewer+ was cleared on 14 March 2025 (K242244, product code QKQ) as an aid to the pathologist for primary diagnosis of FFPE slides, for use with the Hamamatsu NanoZoomer S360MD scanner and the Barco MDPC-8127 display, and is CE marked under the IVDR. That clearance covers the viewer, not a model. The home page presents "one connected, FDA cleared digital pathology workflow" and BxLink as "FDA registered with an FDA-cleared viewer", a platform-level line beside BxCamera, the viewer's AI features and partner algorithms that carry no clearance and no stated regulatory position. The company also calls itself scanner agnostic across more than 75 scanners, while the clearance names one scanner and one display.

AI functions no clearance covers, marketed without the label on them.

Nothing published on how the company's model is tested or governed. BxCamera is described by its training scale and precision claim only, with no evaluation by tissue type, fragment count or specimen size, where measurement is hardest. For partner algorithms, nothing says what Lumea requires before adding one to the marketplace or how a laboratory can test one on its own cases. The tissue devices are designed around set biopsy protocols, and the published benefits are averages with no spread shown.

Nothing published on how model behavior is governed or tested.

Records that let an output be checked, and nothing standing behind it. BxCamera documents each specimen with an image alongside its measurements, RFID tracking keeps a chain of custody record from collection to slide, and the Viewer+ clearance places responsibility for diagnosis and image quality with the reading pathologist. No error figure is published for BxCamera, and no warranty or remediation attaches to a wrong measurement, a compromised specimen from a failed tissue device, or a partner algorithm's result delivered in the workspace. The privacy notice gives patients a right to request correction of their records.

Mechanisms to challenge an output, with nothing standing behind it.

Named laboratory and record systems, with direction described for results. The partners page names laboratory and record systems it integrates with, including Epic, NovoPath, LigoLab, WinSurge, Elea and PathLabs. Viewer+ integrates with a laboratory's existing system, BxLink replaces it and sends results to the EMR, with the company citing 53 percent faster turnaround from automated result integration, and BxCamera auto-populates grossing data through an open API. No interface specification or statement of what flows in each direction is published.

Named systems with one directional writing described.

A hosted platform on a named cloud, with no region stated. Lumea's privacy notice says the platform is accessed through a secure website and data are stored on Amazon Web Services, and the site describes access from any device and location. No region, tenant isolation, retention period or on premises option is stated, and BxCamera runs at the grossing station with results sent to the laboratory system.

A single hosted option with location implied rather than committed.

Prices are published for the devices and the grossing camera, not the software. Lumea's online shop lists BxCamera at $3,995 and tissue consumables with unit prices, such as BxBoard kits from about $15 to $40 and bulk boards at under $8 each, and catalogs are issued for North America and Europe with international distributors. Viewer+, BxLink and marketplace algorithms are sold through a sales conversation with no rate published. The company claims return on investment within three months, a vendor figure with no method.

A price published without full tiers.

Three specialties named, with evidence behind the prostate workflow. Lumea serves urology, dermatology and gastroenterology, with prostate biopsy as the anchor, and says it supports over 40 percent of the US outpatient prostate cancer market; BxLink is built around the prostate biopsy cycle. The biopsy chip has peer reviewed evidence in prostate, the viewer is cleared for FFPE primary diagnosis with one scanner and display, and no published evidence covers dermatology or GI workflows or the company's claim to work with more than 75 scanners.

Coverage named with validation behind part of it.